Terri Sylvestri
Family · Rayville, LANPI 1851443147
Payments from drug & device makers
Across 89 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$387
- Lilly USA, LLC$172
- Astellas Pharma US Inc$161
- AstraZeneca$155
- Supernus Pharmaceuticals, Inc.$154
- Bayer$148
- plus $594 from 15 others
What the payments were for
- Food & beverage$1,65994%
- Education$1106%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $387 |
| Lilly USA, LLC | 10 | $172 |
| Astellas Pharma US Inc | 6 | $161 |
| AstraZeneca | 7 | $155 |
| Supernus Pharmaceuticals, Inc. | 2 | $154 |
| Bayer | 7 | $148 |
| Boehringer Ingelheim | 6 | $101 |
| Novo Nordisk | 6 | $95 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $63 |
| Axsome Therapeutics, Inc. | 3 | $48 |
| Amarin Pharma, Inc. | 2 | $36 |
| Mayne Pharma Commercial LLC | 2 | $33 |
| GSK | 2 | $32 |
| Exact Sciences | 2 | $31 |
| Tactile Systems Technology Inc | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Antares Pharma, Inc. | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $22 |
| Evofem Biosciences, Inc. | 1 | $20 |
| Alkermes, Inc. | 1 | $17 |
How this compares
$1,769 in reported general payments places this provider in the 70th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 62 | $68,750 |
| OzempicSemaglutide | 57 | $59,853 |
| JardianceEmpagliflozin | 48 | $48,326 |
| KerendiaFinerenone | 48 | $43,700 |
| FarxigaDapagliflozin Propanediol | 51 | $43,372 |
| Xigduo XrDapaglifloz Propaned/Metformin | 58 | $41,371 |
| LinzessLinaclotide | 46 | $32,250 |
| Budesonide ErBudesonide | 12 | $27,830 |
| JanuviaSitagliptin Phosphate | 17 | $25,833 |
| RybelsusSemaglutide | 20 | $24,178 |
| ProliaDenosumab | 12 | $20,510 |
| EliquisApixaban | 19 | $19,237 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $13,855 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $12,244 |
| TrulicityDulaglutide | 12 | $11,458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $95 | $84,03177 claims |
| Lilly USA, LLCMounjaro, Trulicity | $172 | $80,20874 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $155 | $57,22773 claims |
| Boehringer IngelheimJardiance, Glyxambi | $101 | $56,98659 claims |
| BayerKerendia | $148 | $43,70048 claims |
| AbbVieLinzess | $387 | $32,25046 claims |
| GSKTrelegy Ellipta | $32 | $12,24419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,610 family providers in Louisiana.
Other family in Rayville
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.